Edgewise Therapeutics, Inc. (EWTX) Financials

EWTX Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 518.5 million 25.3 million
Dec. 31, 2025 552.6 million 30.3 million
Sept. 30, 2025 583.5 million 24.8 million
June 30, 2025 613.3 million 24.3 million

EWTX Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -42.8 million ?
Dec. 31, 2025 -38.4 million -24.9 million
Sept. 30, 2025 -34.9 million 8.1 million
June 30, 2025 -32.6 million 7.7 million

EWTX Net Income

No data available :(

EWTX Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 499.6 million 2.8 million -
Dec. 31, 2025 530.1 million 3.0 million 4.0 million
Sept. 30, 2025 563.3 million 3.2 million 4.2 million
June 30, 2025 594.0 million - 4.4 million

EWTX Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 107.1 million
Dec. 31, 2025 102.9 million
Sept. 30, 2025 105.5 million
June 30, 2025 104.9 million

EWTX Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 260000 42.7 million 11.5 million -
Dec. 31, 2025 183000 43.6 million 12.4 million -
Sept. 30, 2025 89000 37.5 million 9.4 million -
June 30, 2025 50000 33.6 million 9.1 million -

EWTX Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 590000
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - 567000

EWTX

Price: $35.21

52 week price:
12.15
40.77

Earnings Per Share: -1.66 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 74985

Market Capitalization: 4.0 billion

Links: